US2009148428A1PendingUtilityA1

Glycine N-methyltransferase (GNMT) Animal model and use thereof

Assignee: UNIV NAT YANG MINGPriority: Aug 1, 2007Filed: Sep 8, 2008Published: Jun 11, 2009

Est. expiryAug 1, 2027(~1 yrs left)· nominal 20-yr term from priority

A61P 3/08A61P 43/00A61P 35/00A61P 39/02A61P 1/16A01K 67/0276A01K 2227/105A01K 2217/075A01K 2267/0331A01K 2267/03C12N 15/8509

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, fatty liver and other liver disease.

Claims

exact text as granted — not AI-modified

1 . A method for treating or preventing disease caused by aflaoxin B1 (AFB1) in a patient subject comprising administering the patient with an effective amount of Glycine N-methyltransferase (GNMT) or plasmid including GNMT. 
     
     
         2 . The method of  claim 1  wherein the disease is hepatocellular carcinoma (HCC). 
     
     
         3 . The method of  claim 1  wherein the treatment or prevention is made by blocking formation of AFB1-DNA adducts. 
     
     
         4 . The method of  claim 1  wherein the plasmid is directly administered to the body of the patient.

Join the waitlist — get patent alerts

Track US2009148428A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.